Table 2 summarizes ongoing clinical trials for selected non-VEGF angiogenic inhibitors in breast cancer
Statistics All results were represented as means standard error of the mean (SEM)
Collection and assembly of data: KTK, G, CM, EK
Common side effects are typically mild and temporary: Injection site reactions (redness, slight bruising) Mild headaches (usually first week only) Temporary fatigue as your body adjusts Serious side effects are rare when protocols are followed correctly
Thus, new therapeutic strategies should include targeting the IGF axis in malignant cells and tumor microenvironmental drivers in prostate cancer
Research has documented GHRH-Ipamorelin synergistic GH release , characterising combined responses exceeding individual responses at magnitudes comparable to GHRH-GHRP-6 and GHRH-GHRP-2 synergy , confirming that Ipamorelins selective GHS-R1a pharmacology preserves the synergistic GH axis interaction with GHRH through complementary Gq/11 and Gs signalling mechanisms